What is the 13F Pro Quality Score for COYA?

13F Pro ranks Coya Therapeutics, Inc. (COYA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COYA's current score at https://13fpro.ai/company/COYA (free sign-up required for the full ranking).

Where does 13F Pro source COYA data?

All Coya Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Coya Therapeutics, Inc. files with the SEC under CIK 1835022. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COYA in?

Coya Therapeutics, Inc. (COYA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is COYA research updated on 13F Pro?

COYA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Coya Therapeutics, Inc.(COYA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1835022 COYA stock profile & AI dashboard →

13F Pro Quality Score

29.0/100

Rank #2,537 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why COYA Scores 29/100

exact factor attribution · 2026-09-11

COYA's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.5 pts

93th pct

Earnings growth

-1.4 pts

22th pct

Earnings quality

-1.5 pts

35th pct

Institutional flow

-1.7 pts

16th pct

Shareholder dilution

-2.1 pts

8th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-6.1 pts

9th pct

Free cash flow

-6.1 pts

9th pct

Scale

-6.5 pts

7th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

COYA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Coya Therapeutics, Inc. (COYA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COYA at 29.0/100 on a 32-signal composite quality model, placing it at rank #2,537 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Coya Therapeutics, Inc. reports quarterly revenue of $243.7K, net income of $-6.6M. Top institutional holders of COYA by reported 13-F value include DME Capital Management, VANGUARD CAPITAL MANAGEMENT, Alyeska Investment Group, L.P., based on the most recent SEC filings. COYA trades on the Nasdaq exchange and files with the SEC under CIK 1835022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COYA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Coya Therapeutics, Inc. directly from SEC EDGAR. Coya Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 25 and 30 since 2026, currently 29.0 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Coya Therapeutics, Inc.

Quirks, history, and lore behind COYA — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · micro-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
With no approved products yet and a market cap in the tens of millions, it runs on runway — revenue is essentially zero while R&D spending keeps the pipeline moving.
3
The History
Founded in the early 2020s, it emerged from research focused on harnessing the body's own regulatory T cells to fight devastating neurological disease.
4
The Secret
Its lead approach uses low-dose interleukin-2 to expand Tregs naturally — a mechanism that could flip the immune system from attacker to protector of motor neurons.
5
The Lore
Its boldest target is ALS — one of medicine's most stubborn death sentences — and it is also exploring the same Treg platform against Alzheimer's disease.
6
The Giveaway
The name rhymes with a South American country, its ticker is four letters starting with C, and its entire mission is built around Treg immunotherapy for ALS and other neurodegenerative conditions.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$243.7K

Net Income

Q2 2026

$-6.6M

ROIC

Q2 2026

-65.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+123.6% YoY

$7.9MFY 2025

FY22 $0.00FY23 $6.0MFY24 $3.6MFY25 $7.9M

Net Income

-42.6% YoY

$-21.2MFY 2025

FY22 $-12.2MFY23 $-8.0MFY24 $-14.9MFY25 $-21.2M

Operating Income

-30.8% YoY

$-22.6MFY 2025

FY22 $-9.8MFY23 $-7.9MFY24 $-17.2MFY25 $-22.6M

EPS (Diluted)

-29.6% YoY

$-1.27FY 2025

FY22 $-4.73FY23 $-0.79FY24 $-0.98FY25 $-1.27

Total Assets

+12.6% YoY

$50.0MFY 2025

FY22 $8.4MFY23 $41.3MFY24 $44.3MFY25 $50.0M

Op. Cash Flow

-4.4% YoY

$-10.7MFY 2025

FY22 $-7.2MFY23 $-11.2MFY24 $-10.3MFY25 $-10.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$7.9M +123.6%	$3.6M -40.8%	$6.0M	$0.00	—	—
Net Income	$-21.2M -42.6%	$-14.9M -86.3%	$-8.0M +34.8%	$-12.2M -150.3%	$-4.9M	—
Operating Income	$-22.6M -30.8%	$-17.2M -118.3%	$-7.9M +19.5%	$-9.8M -101.5%	$-4.9M	—
EPS (Diluted)	$-1.27 -29.6%	$-0.98 -24.1%	$-0.79 +83.3%	$-4.73 -150.3%	$-1.89	—
Total Assets	$50.0M +12.6%	$44.3M +7.5%	$41.3M +391.5%	$8.4M +75.2%	$4.8M	—
Operating Cash Flow	$-10.7M -4.4%	$-10.3M +8.0%	$-11.2M -54.6%	$-7.2M -85.5%	$-3.9M	—

Get alerted when COYA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Coya Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COYA

DME Capital Management, LP
$13.7M2,335,540 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.9M842,220 sh
Alyeska Investment Group, L.P.
$4.7M800,000 sh
AIGH Capital Management LLC
$3.7M631,912 sh
CM Management, LLC
$2.3M400,000 sh
PRIVATE MANAGEMENT GROUP INC
$2.2M384,217 sh
MARSHALL WACE, LLP
$1.5M249,793 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.3M228,243 sh
RENAISSANCE TECHNOLOGIES LLC
$1.1M192,986 sh
Prosight Management, LP
$994.5K170,000 sh

Fund	Value	Shares
DME Capital Management, LP	$13.7M	2,335,540
VANGUARD CAPITAL MANAGEMENT LLC	$4.9M	842,220
Alyeska Investment Group, L.P.	$4.7M	800,000
AIGH Capital Management LLC	$3.7M	631,912
CM Management, LLC	$2.3M	400,000
PRIVATE MANAGEMENT GROUP INC	$2.2M	384,217
MARSHALL WACE, LLP	$1.5M	249,793
GEODE CAPITAL MANAGEMENT, LLC	$1.3M	228,243
RENAISSANCE TECHNOLOGIES LLC	$1.1M	192,986
Prosight Management, LP	$994.5K	170,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put COYA on your watchlist

Track score changes the day Coya Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COYA a good stock to buy?

13F Pro's AI-powered analysis of Coya Therapeutics, Inc. (COYA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COYA are available on the COYA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. COYA is classified as a small company.

Which hedge funds own COYA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COYA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Coya Therapeutics, Inc.'s investment landscape.